drug
Type 2 Diabetes
Preclinicalupdated 6mo agoby Metallomix Inc
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- tagType 2 Diabetes36 co-mentions · 16 sources
- tagEndocrinology & Metabolism8 co-mentions · 8 sources
- tagCardiology5 co-mentions · 2 sources
- tagObesity4 co-mentions · 3 sources
- tagHeart Failure3 co-mentions · 1 sources
- drugObesity3 co-mentions · 3 sources
- tagType 1 Diabetes2 co-mentions · 1 sources
- drugOzempic2 co-mentions · 2 sources
indications
indications
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Trials studying Type 2 Diabetes
- N/AE3 Diabetes - Closing the Gap in Diabetes Control
- phase3Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
- N/AImpact of SomaSignal Tests on the Choice of Glucose-lowering Medications
- phase3Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
News(10)
- ObesityWeek 2026: Wave outlines case for body composition–based trial designAcross three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw s…biospace · 2d ago
- Deep dive: Cardiovascular calamities and catalystsBioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.biospace · 5d ago
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye diseaseTwelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.biospace · 8d ago
- MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety CommunicationFDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communicationfda_medwatch · 9d ago
- Lowering blood pressure after stroke or with diabetes poses challenges, in research and practiceHigh blood pressure is known as the silent killer. Researchers are finding new ways to fight back.stat · 10d ago
- A treatment revolution is underway in MASHTo build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patie…biospace · 13d ago
- Pfizer, fresh to China’s obesity market, looks to Viagra model to competePfizer is calling upon lessons learned from one of the first drugs ever made available on the internet—Viagra—as it commercializes a new obesity drug in China.biospace · 14d ago
- Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trialA phase 2 trial of Ascletis’ oral GLP-1 drug candidate has hit its primary and secondary endpoints, positioning the Chinese biotech to mount a two-front attack on Eli Lilly’s Foundayo.fiercebiotech · 20d ago
- Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight lossEli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expect…biospace · 21d ago
- Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdownEli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper reductions in blood sugar and body weight across the 80-week study.fiercebiotech · 21d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that